Gary C. Visor

1.4k total citations
27 papers, 365 citations indexed

About

Gary C. Visor is a scholar working on Molecular Biology, Pharmaceutical Science and Infectious Diseases. According to data from OpenAlex, Gary C. Visor has authored 27 papers receiving a total of 365 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 5 papers in Pharmaceutical Science and 4 papers in Infectious Diseases. Recurrent topics in Gary C. Visor's work include Analytical Chemistry and Chromatography (4 papers), Electrochemical sensors and biosensors (4 papers) and Electrochemical Analysis and Applications (3 papers). Gary C. Visor is often cited by papers focused on Analytical Chemistry and Chromatography (4 papers), Electrochemical sensors and biosensors (4 papers) and Electrochemical Analysis and Applications (3 papers). Gary C. Visor collaborates with scholars based in United States, Poland and Switzerland. Gary C. Visor's co-authors include Nicholas Bodor, Richard A. Kenley, William A. Lee, Kenneth C. Cundy, Leo Gu, Jeng‐Pyng Shaw, James A. Fishback, Kenneth F. Soike, Robert G. Strickley and John S. Winterle and has published in prestigious journals such as Advanced Drug Delivery Reviews, International Journal of Pharmaceutics and Pharmaceutical Research.

In The Last Decade

Gary C. Visor

27 papers receiving 336 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Gary C. Visor United States 12 133 74 69 67 59 27 365
Jeffrey A. Ruell United States 9 142 1.1× 92 1.2× 57 0.8× 84 1.3× 64 1.1× 12 428
Shelley R. Rabel United States 11 126 0.9× 99 1.3× 80 1.2× 111 1.7× 25 0.4× 14 420
Tom Alfredson United States 8 98 0.7× 44 0.6× 94 1.4× 41 0.6× 55 0.9× 13 290
Mario A. Quevedo Argentina 14 153 1.2× 137 1.9× 109 1.6× 84 1.3× 40 0.7× 39 519
G.C. Viscomi Italy 13 166 1.2× 36 0.5× 36 0.5× 72 1.1× 82 1.4× 23 502
Michelle A. Long United States 9 79 0.6× 188 2.5× 35 0.5× 56 0.8× 26 0.4× 12 381
Barbara L. Hoesterey United States 10 63 0.5× 94 1.3× 153 2.2× 43 0.6× 41 0.7× 14 358
Margarita C. Briñón Argentina 14 181 1.4× 19 0.3× 209 3.0× 67 1.0× 79 1.3× 48 452
Norman Aubry Canada 14 255 1.9× 25 0.3× 133 1.9× 52 0.8× 86 1.5× 23 545
Kenneth S.E. Su United States 8 235 1.8× 165 2.2× 187 2.7× 30 0.4× 36 0.6× 18 846

Countries citing papers authored by Gary C. Visor

Since Specialization
Citations

This map shows the geographic impact of Gary C. Visor's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gary C. Visor with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gary C. Visor more than expected).

Fields of papers citing papers by Gary C. Visor

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gary C. Visor. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gary C. Visor. The network helps show where Gary C. Visor may publish in the future.

Co-authorship network of co-authors of Gary C. Visor

This figure shows the co-authorship network connecting the top 25 collaborators of Gary C. Visor. A scholar is included among the top collaborators of Gary C. Visor based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gary C. Visor. Gary C. Visor is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cundy, Kenneth C., et al.. (1997). Oral Formulations of Adefovir Dipivoxil: In Vitro Dissolution and in Vivo Bioavailability in Dogs. Journal of Pharmaceutical Sciences. 86(12). 1334–1338. 26 indexed citations
2.
Yuan, Lung‐Chi, et al.. (1996). Stability of cidofovir in 0.9% sodium chloride injection and in 5% dextrose injection. American Journal of Health-System Pharmacy. 53(16). 1939–1943. 6 indexed citations
3.
Guy, Richard H., et al.. (1995). Optimization ofin VitroFlux Through Hairless Mouse Skin of Cidofovir, a Potent Nucleotide Analog. Journal of Pharmaceutical Sciences. 84(6). 750–754. 11 indexed citations
4.
Cundy, Kenneth C., James A. Fishback, Jeng‐Pyng Shaw, et al.. (1994). Oral Bioavailability of the Antiretroviral Agent 9-(2-phosphonylmethoxyethyl)adenine (PMEA) from Three Formulations of the Prodrug Bis(pivaloyloxymethyl)-PMEA in Fasted Male Cynomolgus Monkeys. Pharmaceutical Research. 11(6). 839–843. 59 indexed citations
5.
6.
Strickley, Robert G., et al.. (1989). An Unexpected pH Effect on the Stability of Moexipril Lyophilized Powder. Pharmaceutical Research. 6(11). 971–975. 27 indexed citations
7.
Powell, Michael F., et al.. (1988). Non-steroidal anti-psoriatic prodrugs. II. Citric acid stabilization of lonapalene in various alcohol media and an ointment formulation. International Journal of Pharmaceutics. 44(1-3). 225–234. 3 indexed citations
8.
Visor, Gary C., et al.. (1987). Nasal Absorption of the Calcium Antagonist Nicardipine in Rats and Rhesus Monkeys. Drug Development and Industrial Pharmacy. 13(8). 1329–1343. 3 indexed citations
9.
Visor, Gary C., et al.. (1987). Parenteral formulation development for the positive inotropic agent RS-82856: solubility and stability enhancement through complexation and lyophilization.. PubMed. 41(4). 120–5. 2 indexed citations
10.
Kenley, Richard A., et al.. (1987). Automated Dissolution Testing with Flow-Injection Analysis. Dissolution Profiles for the Antiviral Drugs, Dhpg and Acyclovir, in Capsule Formulations.. Drug Development and Industrial Pharmacy. 13(1). 39–56. 6 indexed citations
11.
Visor, Gary C., et al.. (1986). Stability of ganciclovir sodium (DHPG sodium) in 5% dextrose or 0.9% sodium chloride injections. American Journal of Health-System Pharmacy. 43(11). 2810–2812. 3 indexed citations
12.
Visor, Gary C., et al.. (1986). Intranasal Delivery of Nicardipine in the Rat. Journal of Pharmaceutical Sciences. 75(1). 44–46. 16 indexed citations
13.
Visor, Gary C., et al.. (1985). HPLC Analysis of Thimerosal in Ophthalmic Solution. Comparing Electrochemical with Spectrophotometric Detectors. Pharmaceutical Research. 2(2). 73–75. 9 indexed citations
14.
15.
Visor, Gary C., et al.. (1985). Reverse-Phase HPLC Analysis of the Antiviral Drug, 9-[1,3-Dihydroxy-2-Propoxy Methyl] -Guanine (DHPG), with Amperometric Detection. Journal of Liquid Chromatography. 8(8). 1475–1488. 6 indexed citations
16.
Kenley, Richard A., et al.. (1985). Electrochemistry of Purine Derivatives 2: Correlation of Anodic Differential Pulse Peak Potentials with Hammett Substituent Constants. Journal of Pharmaceutical Sciences. 74(10). 1082–1085. 9 indexed citations
17.
Kenley, Richard A., et al.. (1985). An Automated, Column-Switching HPLC Method for Analyzing Active and Excipient Materials in Both Cream and Ointment Formulations. Drug Development and Industrial Pharmacy. 11(9-10). 1781–1796. 6 indexed citations
18.
Bodor, Nicholas & Gary C. Visor. (1984). Improved Delivery Through Biological Membranes. XVII. A Site-Specific Chemical Delivery System as a Short-Acting Mydriatic Agent. Pharmaceutical Research. 1(4). 168–173. 16 indexed citations
19.
Bodor, Nicholas & Gary C. Visor. (1984). Formation of adrenaline in the iris-ciliary body from adrenalone diesters. Experimental Eye Research. 38(6). 621–626. 37 indexed citations
20.
Visor, Gary C., et al.. (1981). Fluorescence Immunoassay. Journal of Pharmaceutical Sciences. 70(5). 469–475. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jeffrey A. Ruell Breakdown of academic impact, for papers by Shelley R. Rabel Breakdown of academic impact, for papers by Tom Alfredson Breakdown of academic impact, for papers by Mario A. Quevedo Breakdown of academic impact, for papers by G.C. Viscomi Breakdown of academic impact, for papers by Michelle A. Long Breakdown of academic impact, for papers by Barbara L. Hoesterey Breakdown of academic impact, for papers by Margarita C. Briñón Breakdown of academic impact, for papers by Norman Aubry Breakdown of academic impact, for papers by Kenneth S.E. Su
Rankless by CCL
2026